Penwest Pharmaceuticals — Proxy Contest (June 2010)
25 slides from Penwest Pharmaceuticals's proxy contest presentation, Jun 4, 2010
Slide 1: Penwest Pharmaceuticals Co.: The Case for Change
Penwest Pharmaceuticals Co. (NASDAQ: PPCO): The Case for Change Tang Capital Partners, LP Perceptive Life Sciences Master Fund Ltd. June 2010
Slide 2: Disclaimer
Disclaimer In connection with Penwest Pharmaceutical Co.’s upcoming 2010 annual meeting of shareholders (the “Annual Meeting”), Tang Capital Partners, LP (“Tang Capital”) and Perceptive Life Sciences Master Fund Ltd. (“Perceptive”) have filed with the Securities and Exchange Commission (the “SEC”) a
Slide 3: Executive Summary
Executive Summary Tang Capital and Perceptive are the two largest shareholders of Penwest Legacy leadership has failed to deliver value to shareholders Despite approval of shareholder resolution with a 64% vote, Penwest continues to waste corpporate assets aggainst the will of shareholders Penwest i
Slide 4: Background on the Parties
Background on the Parties 4
Slide 5: Our Interests Are Aligned with Yours
Our Interests Are Aligned with Yours o Tang Capital and Perceptive: o Penwest’s officers and directors 1,2 : o Own 41.3% of the Company’s stock o Have invested virtually nothing in Penwest’s stock o Invested $45 million to obtain o Have realized $2.2 million in profits our position from the sale of
Slide 6: Legacy Leadership Has a Proven Track Record of Losing Shareholder Money
Legacy Leadership Has a Proven Track Record of Losing Shareholder Money o Ms. Jennifer Good has been CEO since June 7, 2006 o Stock price performance: down 84%, versus up 15% for the NASDAQ Biotech Index o Mr. Paul Freiman has been Chairman of Penwest since February 2005 o Mr. Freiman was President
Slide 7: In Contrast, We Have a Track Record of Making Money for Investors
In Contrast, We Have a Track Record of Making Money for Investors Tang Capital and Perceptive have established records of delivering superior returns to their investors superior returns to their investors Since inception on 9/3/02 through 5/28/10, Tang Capital has generated a total return of 520%, f
Slide 8: Background on Penwest
Background on Penwest 8
Slide 9: Penwest Has One Principal Asset
Penwest Has One Principal Asset o Penwest has one principal asset: the royalty stream on Opana ER that it receives from licensee Endo Pharmaceuticals o ~$40 million-$45 million this year o Royalty rate ~21% o This income stream is entirely passive and requires zero investment from Penwest 9
Slide 10: Penwest Continues to Squander Its Royalty Asset on Wasteful Endeavors
Penwest Continues to Squander Its Royalty Asset on Wasteful Endeavors o While it has taken some half-measures in response to shareholder pressure, Penwest continues to waste shareholder capital o Over the past year, Penwest has spent approximately $15 million-$16 million on excess overhead and a hig
Slide 11: A0001 Is a High-Risk Gamble and Complete Departure from Core Competency
A0001 Is a High-Risk Gamble and Complete Departure from Core Competency o A0001 is a high-risk gamble that is a complete departure from Penwest’s core competency as a drug delivery company o Penwest is a drug delivery company o Takes already proven drugs usually from partner companies o Formulates t
Slide 12: Last Year's Vote
Last Year’s Vote 12
Slide 13: Our Nominees Were Elected to the Board
Our Nominees Were Elected to the Board Our Nominees Legacy Board Nominees o Edelman 96% o O’Shea 16% o Tang 80% Mr. Edelman and Mr. Tang now represent two of eight board seats * Percentages are of votes cast. 13
Slide 14: Our Shareholder Resolution Was Approved
Our Shareholder Resolution Was Approved o We suspected that other shareholders, and the market generally, agreed that Penwest’s spending would generate a negative return on investment o NPV of Opana ER royalty stream alone has exceeded market capitalization of the Company for most of past two years
Slide 15: Stock Has Responded ONLY to News that Has Moved Penwest Closer to Our Plan
Stock Has Responded ONLY to News that Has Moved Penwest Closer to Our Plan From 6/1/09-6/1/10, stock is up $0.76, or 33% Following election of Tang and Edelman to board stock was up $0 88 or 39%1 Following election of Tang and Edelman to board, stock was up $0.88, or 39%1 Following news of special c
Slide 16: Why Has Nothing Happened?
Why Has Nothing Happened? 16
Slide 17: All Year Long, We Have Been Out-Voted
All Year Long, We Have Been Out-Voted o Because Penwest has a staggered board, we only were able to elect two of eight directors o We have been out-voted by the legacy leadership on all proposals we have made o Implementation of shareholder resolution - rejected o Discontinuation of A0001 - rejected
Slide 18: Vote for our nominees
If you vote for our nominees, you not only will be voting for three highly qualified individuals, but you also will be giving us the ability to deliver on an operating plan that the majority of shareholders voted for 18
Slide 19: Our Proposed Operating Plan
Our Proposed Operating Plan o Curtail substantially all spending on A0001 as quickly as current commitments and scientific prudence allow o Immediately explore ways to monetize this early-stage, high-risk development candidate o corporate partnership o asset sale o Significantly reduce headcount and
Slide 20: Our Proposed Operating Plan (cont.)
Our Proposed Operating Plan (cont.) o Explore ways to monetize TIMERx drug delivery technology o collaborations that make economic sense o sale of the asset o Explore ways to return capital to shareholders o beyond stated plan to pay special cash dividend in 4Q 2010 o in the most tax-efficient manne
Slide 21: Our Nominees
Our Nominees o Roderick Wong, M.D. is a seasoned investment professional with particular expertise in evaluating and investing in biopharmaceutical companies o Has invested in more than 100 health care companies representing more than $1 billion in invested capital o Managing Member of RTW Investmen
Slide 22: Our Nominees (cont.)
Our Nominees (cont.) o Saiid Zarrabian is a seasoned executive with extensive operating experience in the life sciences industry o He has been an effective manager of both growing and maturing companies o President and Chief Executive Officer of Cyntellect, Inc. o President and Chief Operating Offic
Slide 23: Our Nominees (cont.)
Our Nominees (cont.) o John Lemkey has extensive knowledge of financial and tax-related matters o Chief Financial Officer of Tang Capital o Manages accounting, finance and administrative staff, performs financial and valuation analyses, reviews business plans, designs, negotiates and manages complex
Slide 24: Our Pledge to Make the Board Accountable to Shareholders
Our Pledge to Make the Board Accountable to Shareholders o Penwest’s corporate governance is a disgrace o Policies and tactics borne out of explicit desire to suppress shareholder input and avoid accountability o staggered board o establishment of a poison pill If our nominees are elected, we pledge
Slide 25: Contact Information
Contact Information Kevin Tang, Tang Capital Partners, LP 4401 Eastgate Mall San Diego, CA 92121 (858) 200-3830 Joseph Edelman, Perceptive Life Sciences Master Fund Ltd. 499 Park Avenue, 25th Floor New York, NY 10022 (646) 205-5320 Peter Casey, The Altman Group 1200 Wall Street West, 3rd Floor Lyndh